Alexander Mark Schobel net worth and biography

Alexander Schobel Biography and Net Worth

Mark Schobel was appointed as Chief Innovation & Technology Officer of Aquestive in 2014 after serving as the Company’s Chief Executive Officer, Co-President and a member of its Board of Directors since November 2005. From March 2001 to November 2005, he was the Global Head of New Technology and Product Innovation for the Consumer Health Business Unit at Novartis where he pioneered thin film delivery of systemic drugs. Prior to Novartis, Mr. Schobel held various general management positions with Reed & Carnrick Pharmaceuticals, Warner-Lambert, and Pharmaceutical Formulations Inc.

What is Alexander Mark Schobel's net worth?: The estimated net worth of Alexander Mark Schobel is at least $4.03 million as of March 15th, 2024. Schobel owns 984,476 shares of Aquestive Therapeutics stock worth more than $4,026,507 as of April 7th. This net worth estimate does not reflect any other investments that Schobel may own. Learn More about Alexander Mark Schobel's net worth.
How do I contact Alexander Mark Schobel?: The corporate mailing address for Schobel and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Alexander Mark Schobel's contact information.
Has Alexander Mark Schobel been buying or selling shares of Aquestive Therapeutics?: Alexander Mark Schobel has not been actively trading shares of Aquestive Therapeutics in the last ninety days. Most recently, Alexander Mark Schobel sold 50,000 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.00, for a transaction totalling $300,000.00. Following the completion of the sale, the insider now directly owns 984,476 shares of the company's stock, valued at $5,906,856. Learn More on Alexander Mark Schobel's trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Alexander Mark Schobel Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2024	Sell	50,000	$6.00	$300,000.00	984,476
3/8/2024	Sell	25,000	$5.19	$129,750.00	1,040,371
6/8/2022	Buy	45,871	$0.96	$44,036.16	882,871
2/10/2021	Sell	23,460	$6.75	$158,355.00	860,460
2/8/2021	Sell	40,792	$6.50	$265,148.00	860,460
4/29/2020	Sell	40,000	$4.50	$180,000.00	1,022,113
4/27/2020	Sell	40,000	$4.00	$160,000.00	982,113
4/14/2020	Sell	40,000	$3.70	$148,000.00	982,113
12/6/2018	Buy	2,000	$8.69	$17,380.00
11/21/2018	Buy	1,000	$10.25	$10,250.00

Alexander Mark Schobel Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $4.09

$4.09

$4.16

50 Day Range

MA: $3.98

$2.95

$4.37

2 Week Range

Now: $4.09

$2.12

$7.55

Volume

850,616 shs

Average Volume

1,763,910 shs

Market Capitalization

$499.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54